Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
5.3 PATENT ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 COMPANY COMPARITIVE ANALYSIS
5.6 PRICING ANALYSIS
5.7 EVALUATION OF RETAIL VS. DISTRIBUTOR SALES MODELS AND DIRECT SALES STRATEGIES
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , BY PRODUCT
16.1 OVERVIEW
16.2 MIGS STENT
16.2.1 ISTENT
16.2.1.1.1. GENERATION 1
16.2.1.1.2. MARKET VALUE (USD MN)
16.2.1.1.3. MARKET VOLUME (UNITS)
16.2.1.1.4. AVERAGE SELLINF PRICE (USD)
16.2.1.1.5. GENERATION 2
16.2.1.1.6. MARKET VALUE (USD MN)
16.2.1.1.7. MARKET VOLUME (UNITS)
16.2.1.1.8. AVERAGE SELLINF PRICE (USD)
16.2.2 HYDRUS
16.2.2.1.1. MARKET VALUE (USD MN)
16.2.2.1.2. MARKET VOLUME (UNITS)
16.2.2.1.3. AVERAGE SELLINF PRICE (USD)
16.2.3 OTHERS
16.3 MIGS SHUNT
16.3.1 MARKET VALUE (USD MN)
16.3.2 MARKET VOLUME (UNITS)
16.3.3 AVERAGE SELLINF PRICE (USD)
16.4 TRABECTOME
16.4.1 MARKET VALUE (USD MN)
16.4.2 MARKET VOLUME (UNITS)
16.4.3 AVERAGE SELLINF PRICE (USD)
16.5 MICRO-IMPLANTS
16.5.1 MARKET VALUE (USD MN)
16.5.2 MARKET VOLUME (UNITS)
16.5.3 AVERAGE SELLINF PRICE (USD)
16.6 MICRO CATHETERS
16.6.1 MARKET VALUE (USD MN)
16.6.2 MARKET VOLUME (UNITS)
16.6.3 AVERAGE SELLINF PRICE (USD)
16.7 OTHERS
17 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , BY TARGET
17.1 OVERVIEW
17.2 TRABECULAR MESHWORK
17.3 SUPRACHOROIDAL SPACE
17.4 SUBCONJUNCTIVAL FILTRATION
17.5 REDUCING AQUEOUS PRODUCTION
17.6 OTHERS
18 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , BY SURGERY TYPE
18.1 OVERVIEW
18.2 GLAUCOMA IN CONJUNCTION WITH CATARACT
18.3 STAND-ALONE GLAUCOMA
18.4 OTHERS
19 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , BY END USER
19.1 OVERVIEW
19.2 HOSPITALS OUTPATIENTS DEPARTMENT (HOPD)
19.3 OPHTHALMOLOGY CLINICS
19.4 AMBULATORY SURGERY CENTERS (ASCS)
19.5 OTHERS
20 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.4 ONLINE STORES
20.5 OTHERS
21 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: U.S.
21.2 MERGERS & ACQUISITIONS
21.3 NEW PRODUCT DEVELOPMENT & APPROVALS
21.4 EXPANSIONS
21.5 REGULATORY CHANGES
21.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , SWOT AND DBMR ANALYSIS
23 U.S. MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET , COMPANY PROFILE
23.1 ABBVIE
23.1.1 COMPANY OVERVIEW
23.1.2 REVENUE ANALYSIS
23.1.3 GEOGRAPHIC PRESENCE
23.1.4 PRODUCT PORTFOLIO
23.1.5 RECENT DEVELOPEMENTS
23.2 GLAUKOS CORPORATION
23.2.1 COMPANY OVERVIEW
23.2.2 REVENUE ANALYSIS
23.2.3 GEOGRAPHIC PRESENCE
23.2.4 PRODUCT PORTFOLIO
23.2.5 RECENT DEVELOPEMENTS
23.3 BVI
23.3.1 COMPANY OVERVIEW
23.3.2 REVENUE ANALYSIS
23.3.3 GEOGRAPHIC PRESENCE
23.3.4 PRODUCT PORTFOLIO
23.3.5 RECENT DEVELOPEMENTS
23.4 ZIEMER OPHTHALMIC SYSTEMS AG
23.4.1 COMPANY OVERVIEW
23.4.2 REVENUE ANALYSIS
23.4.3 GEOGRAPHIC PRESENCE
23.4.4 PRODUCT PORTFOLIO
23.4.5 RECENT DEVELOPEMENTS
23.5 ALCON
23.5.1 COMPANY OVERVIEW
23.5.2 REVENUE ANALYSIS
23.5.3 GEOGRAPHIC PRESENCE
23.5.4 PRODUCT PORTFOLIO
23.5.5 RECENT DEVELOPEMENTS
23.6 NOVA EYE MEDICAL LIMITED
23.6.1 COMPANY OVERVIEW
23.6.2 REVENUE ANALYSIS
23.6.3 GEOGRAPHIC PRESENCE
23.6.4 PRODUCT PORTFOLIO
23.6.5 RECENT DEVELOPEMENTS
23.7 JOHNSON & JOHNSON SURGICAL VISION, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
23.7.1 COMPANY OVERVIEW
23.7.2 REVENUE ANALYSIS
23.7.3 GEOGRAPHIC PRESENCE
23.7.4 PRODUCT PORTFOLIO
23.7.5 RECENT DEVELOPEMENTS
23.8 SANTEN PHARMACEUTICAL
23.8.1 COMPANY OVERVIEW
23.8.2 REVENUE ANALYSIS
23.8.3 GEOGRAPHIC PRESENCE
23.8.4 PRODUCT PORTFOLIO
23.8.5 RECENT DEVELOPEMENTS
23.9 SIGHT SCIENCES, INC.
23.9.1 COMPANY OVERVIEW
23.9.2 REVENUE ANALYSIS
23.9.3 GEOGRAPHIC PRESENCE
23.9.4 PRODUCT PORTFOLIO
23.9.5 RECENT DEVELOPEMENTS
23.1 SANTEN PHARMACEUTICAL CO., LTD
23.10.1 COMPANY OVERVIEW
23.10.2 REVENUE ANALYSIS
23.10.3 GEOGRAPHIC PRESENCE
23.10.4 PRODUCT PORTFOLIO
23.10.5 RECENT DEVELOPEMENTS
23.11 BELKIN VISION.
23.11.1 COMPANY OVERVIEW
23.11.2 REVENUE ANALYSIS
23.11.3 GEOGRAPHIC PRESENCE
23.11.4 PRODUCT PORTFOLIO
23.11.5 RECENT DEVELOPEMENTS
23.12 ISTAR MEDICAL
23.12.1 COMPANY OVERVIEW
23.12.2 REVENUE ANALYSIS
23.12.3 GEOGRAPHIC PRESENCE
23.12.4 PRODUCT PORTFOLIO
23.12.5 RECENT DEVELOPEMENTS
23.13 OERTLI INSTRUMENTE AG
23.13.1 COMPANY OVERVIEW
23.13.2 REVENUE ANALYSIS
23.13.3 GEOGRAPHIC PRESENCE
23.13.4 PRODUCT PORTFOLIO
23.13.5 RECENT DEVELOPEMENTS
23.14 BAUSCH + LOMB
23.14.1 COMPANY OVERVIEW
23.14.2 REVENUE ANALYSIS
23.14.3 GEOGRAPHIC PRESENCE
23.14.4 PRODUCT PORTFOLIO
23.14.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
24 RELATED REPORTS
25 CONCLUSION
26 QUESTIONNAIRE
27 ABOUT DATA BRIDGE MARKET RESEARCH
